Ionis Pharmaceuticals IONS Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties
Interest Expense And Amortization Of Issuance Costs Related To Sale Of Future Royalties at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:InterestExpenseAndAmortizationOfIssuanceCostsRelatedToSaleOfFutureRoyalties.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties?
- Ionis Pharmaceuticals (IONS) reported interest expense and amortization of issuance costs related to sale of future royalties of $17.34M in Q1 2026.
- How has Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties changed year-over-year?
- Ionis Pharmaceuticals's interest expense and amortization of issuance costs related to sale of future royalties decreased by 7.9% year-over-year, from $18.82M to $17.34M.
- What does interest expense and amortization of issuance costs related to sale of future royalties mean?
- Interest and financing costs associated with selling future royalty rights.
- How do you interpret interest expense and amortization of issuance costs related to sale of future royalties?
- A decrease suggests the company is reducing its reliance on royalty-based financing or has paid down these specific obligations.
- How does interest expense and amortization of issuance costs related to sale of future royalties compare across companies?
- Specific to biotech or pharma companies that utilize royalty monetization as a funding mechanism.